US EditionPublished • loading... • Updated
Adimab Reports Strong Partnering Year for 2025
Adimab expanded its global collaborations in 2025, initiating 75 new therapeutic programs and reaching over 650 royalty-bearing programs to date, with 50 technical milestones achieved.
- On Jan. 12, 2026, Adimab, LLC announced partnerships with 23 companies and launched 75 new therapeutic programs in 2025, according to a Lebanon, N.H., press release.
- Using its proprietary yeast-based discovery and engineering platform, Adimab enables partners to rapidly expand biologics pipelines through broad technology access arrangements.
- Recently, anti-TCR heavy-chain antibodies were added to Adimab's toolkit and more than 20 partners use heterodimerization mutation sets, while the company discovers antibodies in IgG and VHH formats.
- The company achieved 50 technical and development milestones in 2025, and many partners retain contractual rights to start additional royalty-bearing programs, Adimab reported.
- Since 2009, Adimab has partnered with over 140 pharmaceutical and biotechnology companies, and its technology has been implemented at GSK, Biogen, Novo Nordisk, Merck, Lilly, and Takeda.
Insights by Ground AI
19 Articles
19 Articles
The Dispatch+18 Reposted by 18 other sources
Adimab Reports Strong Partnering Year for 2025
– 23 Overall Partnerships in 2025 –
Coverage Details
Total News Sources19
Leaning Left3Leaning Right4Center4Last UpdatedBias Distribution37% Center, 36% Right
Bias Distribution
- 37% of the sources are Center, 36% of the sources lean Right
37% Center
L 27%
C 37%
R 36%
Factuality
To view factuality data please Upgrade to Premium
